Product Description
NG-641 is an oncolytic adenoviral vector designed to deliver genes to tumor cells that produce proteins that target tumor-associated stromal fibroblasts.
Mechanisms of Action: FAP Inhibitor, CD3 Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Akamis Bio
Company Location: Europe
Company Founding Year: 2016
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Head and Neck Cancer|Oncology Solid Tumor Unspecified|Squamous Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04053283 |
STAR | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2024-08-31 |
12% |
2025-03-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05043714 |
NEBULA | P1 |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma |
2024-08-31 |
21% |
2025-03-27 |
Primary Endpoints |
NCT04830592 |
MOAT | P1 |
Completed |
Squamous Cell Carcinoma|Head and Neck Cancer |
2023-12-07 |
21% |
2025-08-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |